Management of Rhabdomyolysis in Liver Cirrhosis

Fluid Management and Medication

The European Association for the Study of the Liver recommends monitoring fluid status carefully to avoid precipitating or worsening ascites, using crystalloids rather than colloids for initial volume expansion, with a target urine output of approximately 300 mL/hour 1, 2
The American Association for the Study of Liver Diseases suggests discontinuing any potentially causative medications, particularly statins, NSAIDs, aminoglycosides, ACE inhibitors, and angiotensin receptor blockers, to prevent further muscle breakdown and renal injury 3

The American Association for the Study of Liver Diseases recommends maintaining sodium restriction (<5 g/day) and using diuretics cautiously, with aldosterone antagonists as the mainstay (spironolactone 50-100 mg/day), for patients with ascites 1, 4
The International Ascites Club suggests considering large volume paracentesis for grade 3 ascites with albumin replacement (8 g/L of ascites removed) 3

The American Society of Nephrology advises avoiding nephrotoxic agents and considering terlipressin for hepatorenal syndrome if available, with close monitoring of serum electrolytes, particularly potassium 5
The European Renal Association recommends monitoring serum electrolytes closely, particularly potassium, as both rhabdomyolysis and diuretics can cause significant disturbances 2

The American Society of Nephrology suggests considering continuous renal replacement therapy for volume overload unresponsive to diuretics 2
The European Society for Clinical Nutrition and Metabolism recommends optimizing nutritional status with adequate protein intake (1.2-1.5 g/kg) to prevent recurrent episodes of rhabdomyolysis 7

The American Association for the Study of Liver Diseases recommends considering liver transplant evaluation for eligible patients with recurrent episodes of rhabdomyolysis and decompensated cirrhosis 6